Ahmed Ezz is Managing Director of Neuraxpharm Middle East, where he leads the company’s entry and affiliate build-out across the GCC and wider MENA region. He is responsible for establishing Neuraxpharm’s regional presence, from corporate setup and regulatory and market access strategy through partner engagement, portfolio registration, and the launch of the company’s CNS-focused portfolio in the Middle East.

Ahmed brings nearly two decades of pharmaceutical industry experience across MENA, with a track record of bringing innovative specialty therapies to GCC markets in collaboration with global partners including AbbVie, Kyowa Kirin, UCB, Chiesi Global Rare Diseases, Juvisé, Serb, Sunovion, Abiogen, Illumina, and Veracyte.

Prior to Neuraxpharm, he served as Senior Director and Group Therapy Area Director for GI, Metabolic, and Rare Diseases at NewBridge Pharmaceuticals, where he led a cross-functional team of across 10 markets and managed a portfolio of nine specialty brands, including multiple FDA- and EMA-approved products.

Earlier in his career, he led NewBridge’s regional CNS franchise, overseeing the launch of neurology and psychiatry portfolio across the region.

He holds an MBA with Distinction from the University of Leicester, a Diploma in Strategic Management and Leadership from the Chartered Institute of Management in London, and a Bachelor of Pharmaceutical Sciences with Honors from Ain Shams University, Cairo.